Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial
Authors:
Open Access
- 22 February 2017
- journal article
- research article
- Published by American Society for Microbiology in mSphere
- Vol. 2 (1) , e00310-16
Abstract
Multidrug resistance among bacterial pathogens is an ongoing global problem and renders antimicrobial agents ineffective at treating bacterial infections. In the health care setting, infections caused by multidrug-resistant (MDR) Gram-negative bacteria can cause increased mortality, longer hospital stays, and higher treatments costs. The aim of the Tigecycline Evaluation and Surveillance Trial (TEST) is to assess the in vitro antimicrobial activities of tigecycline and other contemporary agents against clinically relevant pathogens. This paper presents antimicrobial activity data from the TEST study between 2004 and 2014 and examines global rates of MDR Gram-negative isolates, including Acinetobacter baumannii , Pseudomonas aeruginosa , and members of the Enterobacteriaceae , during this time. Our results show that tigecycline retained in vitro activity against many MDR Gram-negative pathogens over the study period, while rates of MDR A. baumannii increased globally. Using these findings, we hope to highlight the current status of multidrug resistance in medical facilities worldwide.Keywords
This publication has 17 references indexed in Scilit:
- Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013Annals of Clinical Microbiology and Antimicrobials, 2015
- Molecular mechanisms of antibiotic resistanceNature Reviews Microbiology, 2014
- Multidrug-Resistant Gram-Negative Bacterial Infections: Are you Ready for the Challenge?Current Clinical Pharmacology, 2014
- Antibiotics and Bacterial Resistance in the 21st CenturyPerspectives in Medicinal Chemistry, 2014
- Clinical management of infections caused by multidrug-resistant EnterobacteriaceaeTherapeutic Advances in Infectious Disease, 2013
- Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPEThe Journal of Infectious Diseases, 2008
- Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative BacilliAntimicrobial Agents and Chemotherapy, 2008
- Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobialInternational Journal of Antimicrobial Agents, 2007
- Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobialDiagnostic Microbiology and Infectious Disease, 2007
- Disk diffusion susceptibility test development for the new glycylcycline, GAR-936Diagnostic Microbiology and Infectious Disease, 1999